Drug Trial Radar · NCT05417087
Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
Last checked: Nov 20, 2026Latest source record: Apr 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Jun 27, 2022
Primary completion
Sep 2, 2022
Study completion Sep 2, 2022
Sponsor
- Lead sponsor
- Seasons Biotechnology (Taizhou) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 14, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 25 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
An open label, randomized, three-period, three-treatment \[Treatment A (test product administered without water), Treatment B (test product administered with water) and Treatment C (Reference product administered with water)\], six-sequence, crossover, balanced, single dose oral bioequivalence study.
Conditions
- Major Depressive Disorder (MDD)
Interventions
Vortioxetine Hemihydrobromide Orally Disintegrating TabletsDrug
Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine
Vortioxetine Hydrobromide TabletsDrug
Vortioxetine Hydrobromide Tablets 20mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma samples will be tested. PK parameter Cmax will be reported. Ratios of PK parameters on SF001 ODT and Trintellix fall within 80.00% to 125.00%Time frame: In each period, total 28 blood samples will be collected at pre-dose (0.0 hour) and until 240 hours post dose
- Plasma samples will be tested. PK parameter AUCi will be reported. Ratios of PK parameters on SF001 ODT and Trintellix fall within 80.00% to 125.00%Time frame: In each period, total 28 blood samples will be collected at pre-dose (0.0 hour) and until 240 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research Limited
Ahmedabad, Gujarat, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.